Jidinum

Sitagliptin, the active ingredient in Jidinum, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when combined with diet and exercise.

GNH USA supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution through its experienced network of partners.

Sitagliptin is used to improve glycaemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when added to diet and exercise. - Inadequate control with metformin alone: provides additional glucose lowering as adjunct therapy. - Metformin intolerance: serves as an alternative oral antidiabetic option. - Combination with sulfonylureas: enhances overall glycaemic reduction while monitoring hypoglycaemia risk. - Use in elderly patients: offers glucose control with low risk of hypoglycaemia.

Sitagliptin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection - Diarrhoea

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Bullous pemphigoid

When prescribing sitagliptin, clinicians should consider several safety precautions. - Renal function: assess baseline renal function and adjust use in patients with severe impairment. - Hepatic impairment: use with caution in patients with liver disease; monitor liver enzymes. - Hypersensitivity: discontinue immediately if signs of allergic reaction such as rash or swelling appear. - Cardiovascular disease: monitor patients with a history of heart failure for any worsening symptoms. - Pregnancy and lactation: safety not established; avoid unless potential benefits justify the risk. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin: combined use may increase risk of hypoglycaemia. - Sulfonylureas: concurrent therapy can potentiate hypoglycaemic events.

Moderate Interactions (Monitor Closely): - Rifampin: enzyme induction may reduce sitagliptin plasma concentrations. - Diuretics: may alter glucose control; monitor blood sugar. - ACE inhibitors: observe renal function when used together.